RCUS Relative Valuation
RCUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCUS is overvalued; if below, it's undervalued.
Historical Valuation
Arcus Biosciences Inc (RCUS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -6.37. The fair price of Arcus Biosciences Inc (RCUS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 25.26 USD , Arcus Biosciences Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：25.26
Fair
Undervalued
-5.85
PE
1Y
3Y
5Y
Trailing
Forward
-5.85
EV/EBITDA
Arcus Biosciences Inc. (RCUS) has a current EV/EBITDA of -5.85. The 5-year average EV/EBITDA is -3.95. The thresholds are as follows: Strongly Undervalued below -13.60, Undervalued between -13.60 and -8.77, Fairly Valued between 0.88 and -8.77, Overvalued between 0.88 and 5.71, and Strongly Overvalued above 5.71. The current Forward EV/EBITDA of -5.85 falls within the Historic Trend Line -Fairly Valued range.
-4.66
EV/EBIT
Arcus Biosciences Inc. (RCUS) has a current EV/EBIT of -4.66. The 5-year average EV/EBIT is -3.19. The thresholds are as follows: Strongly Undervalued below -10.28, Undervalued between -10.28 and -6.73, Fairly Valued between 0.36 and -6.73, Overvalued between 0.36 and 3.90, and Strongly Overvalued above 3.90. The current Forward EV/EBIT of -4.66 falls within the Historic Trend Line -Fairly Valued range.
30.21
PS
Arcus Biosciences Inc. (RCUS) has a current PS of 30.21. The 5-year average PS is 14.07. The thresholds are as follows: Strongly Undervalued below 0.59, Undervalued between 0.59 and 7.33, Fairly Valued between 20.81 and 7.33, Overvalued between 20.81 and 27.55, and Strongly Overvalued above 27.55. The current Forward PS of 30.21 falls within the Strongly Overvalued range.
-7.42
P/OCF
Arcus Biosciences Inc. (RCUS) has a current P/OCF of -7.42. The 5-year average P/OCF is -7.25. The thresholds are as follows: Strongly Undervalued below -44.14, Undervalued between -44.14 and -25.70, Fairly Valued between 11.19 and -25.70, Overvalued between 11.19 and 29.64, and Strongly Overvalued above 29.64. The current Forward P/OCF of -7.42 falls within the Historic Trend Line -Fairly Valued range.
-9.16
P/FCF
Arcus Biosciences Inc. (RCUS) has a current P/FCF of -9.16. The 5-year average P/FCF is -7.97. The thresholds are as follows: Strongly Undervalued below -32.62, Undervalued between -32.62 and -20.30, Fairly Valued between 4.35 and -20.30, Overvalued between 4.35 and 16.68, and Strongly Overvalued above 16.68. The current Forward P/FCF of -9.16 falls within the Historic Trend Line -Fairly Valued range.
Arcus Biosciences Inc (RCUS) has a current Price-to-Book (P/B) ratio of 6.20. Compared to its 3-year average P/B ratio of 2.43 , the current P/B ratio is approximately 155.49% higher. Relative to its 5-year average P/B ratio of 2.80, the current P/B ratio is about 121.49% higher. Arcus Biosciences Inc (RCUS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -16.16%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.89% , the current FCF yield is about -100.00% lower.
6.20
P/B
Median3y
2.43
Median5y
2.80
-14.63
FCF Yield
Median3y
-16.16
Median5y
-6.89
Competitors Valuation Multiple
The average P/S ratio for RCUS's competitors is 7.32, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -45.83%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RCUS increased by 69.64% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -191.67 to -519.23.
The secondary factor is the Revenue Growth, contributed -45.83%to the performance.
Overall, the performance of RCUS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Arcus Biosciences Inc (RCUS) currently overvalued or undervalued?
What is Arcus Biosciences Inc (RCUS) fair value?
How does RCUS's valuation metrics compare to the industry average?
What is the current P/B ratio for Arcus Biosciences Inc (RCUS) as of Dec 05 2025?
What is the current FCF Yield for Arcus Biosciences Inc (RCUS) as of Dec 05 2025?
What is the current Forward P/E ratio for Arcus Biosciences Inc (RCUS) as of Dec 05 2025?